PepGen Inc

PEPG

Company Profile

  • Business description

    PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

  • Contact

    321 Harrison Avenue
    8th Floor
    BostonMA02118
    USA

    T: +1 781 797-0979

    https://www.pepgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    76

Stocks News & Analysis

stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.
stocks

Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?

Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
stocks

Investing in gold miners

Exploring the commodity as prices continue to soar. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,825.1020.900.24%
CAC 408,178.5414.430.18%
DAX 4022,513.4298.60-0.44%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,732.4632.26-0.37%
HKSE22,620.33805.963.69%
NASDAQ20,026.7781.130.41%
Nikkei 22539,149.43312.04-0.79%
NZX 50 Index12,989.1883.200.64%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,555.8015.800.19%
SSE Composite Index3,346.7214.240.43%

Market Movers